Aciclovir Ciclum

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Aciclovir Ciclum

Aciclovir Ciclum is a specific pharmaceutical product containing the active ingredient Aciclovir, which is classified as a potent antiviral medicine. It functions as a synthetic nucleoside analog, meaning it is a chemically engineered compound designed to interfere directly with the reproductive processes of certain viruses.


Quick Facts: Aciclovir Ciclum Identity

Property Description
Active Ingredient Aciclovir
Form Oral tablets, topical cream, intravenous solution
Pharmacological Class Antiviral, Nucleoside analog
General Purpose To slow down viral multiplication and spread
Origin Synthetic (guanosine derivative)

Aciclovir Ciclum: Definition and Pharmacological Identity

Aciclovir Ciclum is an antiviral agent whose active component, Aciclovir, is a synthetic compound derived from guanosine, one of the purine nucleosides fundamental to DNA. It is categorized pharmacologically as a direct-acting antiviral, specifically under the group of Nucleosides and nucleotides (excl. reverse transcriptase inhibitors). The compound is recognized internationally for its role as a key treatment for infections caused by the Herpes simplex virus and Varicella-zoster virus. This indicates that the medication is an established option for managing these specific viral illnesses.

This classification is crucial as it defines the drug’s highly selective function. Unlike broader agents, Aciclovir is designed to be recognized and activated primarily by enzymes unique to the target virus, ensuring its therapeutic action is concentrated on infected cells and not healthy host cells. Aciclovir Ciclum, as a brand formulation, is typically available as a prescription-only medicine, underscoring its established medical oversight.


Composition, Form, and General Therapeutic Purpose

The core composition of Aciclovir Ciclum involves the single active ingredient Aciclovir formulated into various dosage forms suitable for different therapeutic approaches. This versatility allows for the administration of the active ingredient either systemically, using oral tablets or intravenous solutions, or locally on the skin via a topical cream base.

The overarching therapeutic purpose of Aciclovir Ciclum is to limit the growth and spread of targeted viruses. By disrupting the replication cycle, the medicine reduces the total viral load, thereby enabling the body’s own immune response to manage the infection more effectively and generally lessening the severity and duration of the illness. Aciclovir remains a standard agent in the management of these viral infections, highlighting its sustained relevance and efficacy in controlling outbreaks.

Regulatory References

  1. Acyclovir: MedlinePlus Drug Information
Advertisements

What side effects are possible with Aciclovir Ciclum?

Possible side effects and safety information

The safety profile of Aciclovir Ciclum is defined by formal classifications detailing the frequency and type of possible adverse reactions, as documented in regulatory sources like the EMA and FDA. This information is organized by the body system affected and the statistical likelihood of occurrence.


Frequency Classification of Adverse Effects

Classification Examples of Documented Effects
Common (ge 1/100 to < 1/10) Headache, dizziness, nausea, vomiting, diarrhea, abdominal pain, fatigue, fever, pruritus (itching), and rashes.
Uncommon (ge 1/1,000 to < 1/100) Urticaria (hives) and accelerated diffuse hair loss.
Rare (ge 1/10,000 to < 1/1,000) Anaphylaxis, angioedema, reversible increases in liver-related enzymes and bilirubin, and increases in blood urea nitrogen and creatinine.
Very Rare (< 1/10,000) Anemia, leukopenia, thrombocytopenia, confusion, hallucinations, convulsions, somnolence, encephalopathy, hepatitis, jaundice, and acute renal failure.

Safety Considerations and Restrictions

Certain reactions are classified as Serious Adverse Reactions, which include acute renal failure, anaphylaxis, and severe neurological events like convulsions and encephalopathy. These are recognized in official labeling as clinically significant, though Very Rare.

Population-Specific Safety Notes address the potential for an increased risk of neurological adverse reactions, such as confusion, in older adults and individuals with pre-existing renal impairment. Safety documentation emphasizes that the maintenance of adequate hydration is required, especially during high-dose administration, as inadequate hydration is often associated with the occurrence of renal effects. The label also specifies that neurological adverse reactions are generally noted as reversible upon cessation of treatment.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Aciclovir overdose defines the condition primarily through severe effects on the Central Nervous System (CNS) and the renal system. Documented CNS manifestations include agitation, confusion, drowsiness, and hallucinations. These can lead to life-threatening outcomes such as seizures and loss of consciousness.

Renal toxicity is identified by systemic signs including decreased urination and swelling of the extremities, which may progress to acute renal failure due to crystal precipitation in the kidneys. Nausea and vomiting are also documented presentations of overexposure.

Immediate medical attention must be sought for any suspected overexposure. Regulatory instructions are explicit: emergency services must be contacted immediately if the affected individual collapses, experiences a seizure, or is unable to be awakened. Since there is no specific antidote, management focuses strictly on symptomatic and supportive care. Hemodialysis is documented as a key procedural measure to accelerate the removal of Aciclovir from the systemic circulation.

Furthermore, the official information notes that the risk of toxicity, especially CNS effects, is heightened in specific populations, notably elderly patients and individuals with pre-existing kidney impairment or dehydration.

Advertisements

Therapeutic Uses of Aciclovir Ciclum

What Aciclovir Ciclum Treats: Main Uses and Benefits

Aciclovir Ciclum is primarily used to provide symptomatic relief and supportive management during acute episodes caused by certain viruses, particularly those belonging to the herpes virus family. This medication is commonly used to help relieve symptoms related to physical discomfort and may assist in easing the course of the visible manifestations. It is relevant in conditions like shingles, chickenpox, and first-time or repeat outbreaks of genital herpes. This focus on symptomatic domains contributes to easing the overall symptom load for the patient.

Symptomatic Relief for Acute Episodes

This medication is applied across domains where additional symptomatic support is needed, particularly in conditions characterized by periods of heightened symptoms. It is often used when symptoms intensify and supportive relief is needed, helping to address symptom clusters that may appear suddenly or intensify over time. The key benefit is to provide support that helps ease the overall symptom burden during acute, recurrent episodes, contributing to improved comfort during these periods.

Support for Pronounced and Disruptive Manifestations

Aciclovir Ciclum is relevant in contexts marked by increased discomfort or tension, applied when symptoms create noticeable physiological strain or interfere with daily functioning. It is helpful in situations where multiple symptoms occur together, requiring supportive management. It is applied to ease challenging symptoms that interfere with functional stability and offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.


Quick Fact: Relief for Symptoms that interfere with daily functioning and those associated with acute or episodic changes.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Aciclovir Ciclum?

This section details the officially documented population eligibility and non-eligibility for Aciclovir (Aciclovir Ciclum), as defined by regulatory labeling.

Eligibility Status Applicable Population or Condition
Contraindicated Use Patients with known hypersensitivity to aciclovir, valaciclovir, or any component of the specific formulation are strictly ineligible.
Absolute Exclusion Patients with rare hereditary problems like galactose intolerance or Lapp lactase deficiency are ineligible for certain oral tablets.
Conditional Use Patients with renal impairment require a mandatory adjustment to the regimen due to the drug’s renal clearance.
Geriatric Caution Elderly patients (over 65) must have dose reduction considered, as they are likely to have reduced renal function.
Restricted Use In severely immune-compromised individuals, prolonged use risks the selection of resistant virus strains.
Pregnancy Status Use is authorized only when the potential therapeutic benefits outweigh the possibility of unknown risks.
Lactation Status Generally considered acceptable for use due to minimal excretion of the medicine into breast milk.

These eligibility rules are structured by regulators to define absolute contraindications based on allergy or excipients, and to establish conditional use for populations with physiological factors that affect drug clearance or risk profile. Conditions such as renal impairment or advanced age necessitate pre-treatment evaluation and close monitoring, as officially documented in the prescribing information. Use in younger children may also be constrained by formulation.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interactions for aciclovir that primarily affect its clearance from the body via the kidneys. These interactions are categorized as clinically significant, requiring careful evaluation and monitoring when co-administered.

Documented Interacting Medicines and Categories

Category/Specific Medicine Interaction Description
Probenecid (Uricosuric agent) Increases systemic exposure (AUC) and half-life of aciclovir.
Cimetidine (H2-receptor antagonist) Increases systemic exposure (AUC) of aciclovir.
Potentially Nephrotoxic Agents May increase the risk of renal dysfunction when co-administered.
Mycophenolate Mofetil Increased plasma exposure of both aciclovir and the inactive metabolite of mycophenolate mofetil.

Mechanistic and Procedural Constraints

The increased exposure of aciclovir when used with probenecid and cimetidine is attributed to the competitive inhibition of active renal tubular secretion of aciclovir in the kidneys. This mechanism reduces the rate at which aciclovir is excreted. Official documents emphasize that caution must be exercised when aciclovir is administered concurrently with other medicines known to be potentially nephrotoxic. Adequate hydration is a procedural constraint that should be maintained when using aciclovir with any potentially nephrotoxic agent to help mitigate the risk of renal injury.

Advertisements

Mechanism of Action

How Aciclovir Ciclum Works

Activation Mediated by Viral Thymidine Kinase

The drug's mechanism begins by targeting a specific Viral Enzyme (Thymidine Kinase), which is predominantly present in virus-infected cells. This enzyme performs the crucial first step of chemically modifying Aciclovir into its active form. This targeted activation ensures the drug is primarily localized and converted where the viral replication machinery is active.


Blockade of Viral DNA Replication

Once activated, the drug functions as a false nucleotide that interferes directly with the virus's ability to reproduce. It is incorporated into the growing Viral DNA strand by the Viral DNA Polymerase enzyme, immediately causing an obligatory DNA chain termination. This key mechanistic cascade fundamentally halts the synthesis of new genetic material for the virus.


Consequence on Systemic Viral Population Density

The combined molecular action of activation and DNA synthesis blockade prevents the virus from multiplying and creating new infectious particles. The resulting physiological change is a functional limit on the expansion of the systemic viral population. This functional limitation on multiplication controls the rate of viral propagation across cellular systems.

Advertisements

Dosage and Administration Information

How to Use Aciclovir Ciclum: Official Administration Guidelines

The usage of Aciclovir is governed by specific administrative instructions detailed in regulatory prescribing information, which define the required route, dose, frequency, and duration patterns. This standardized protocol ensures consistency across various clinical scenarios.


Usage Feature Official Regulatory Guideline
Route of Administration Oral ingestion (tablets, capsules, suspension), Intravenous (IV) Infusion, and Topical application (cream).
Standard Dosing Schedule Regimens are indication-specific: Oral doses range from 200 mg to 800 mg per dose. IV administration requires a weight-based dose of 5 mg/kg or 10 mg/kg.
Frequency and Timing Acute oral treatment often requires administration up to five times daily, whereas suppressive therapy is typically dosed twice daily. Oral formulations may be administered with or without food.
Course Duration The length of treatment is fixed, commonly lasting 5, 7, or 10 days for acute episodes. Suppressive therapy may be continued for up to 12 months, followed by formal re-evaluation.
Procedural Conditions Therapy must be formally initiated at the earliest sign or symptom of recurrence. IV infusion must be administered slowly over a period of at least one hour to adhere to specified procedural constraints.
Population-Specific Rule A mandatory dosage reduction is required for patients with documented renal impairment, with specific adjustments determined by the patient's creatinine clearance.

Connection to the Overall Use Protocol

The official instructions establish a standardized protocol governing the amount and timing of the medicine's delivery. This structure mandates specific fixed-dose or weight-based quantities and dictates that acute use must follow a strict, fixed-duration course. Furthermore, the protocol includes a formal requirement for dose modification to manage altered elimination in patients with reduced kidney function.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Investigations

Research has explored the effects of the compound and its potential involvement with key receptors. Studies have focused on how the compound may interfere with the viral replication process.

One clinical trial in 2020 evaluated the change in symptoms reported by participants over a two-week period. Research has investigated the compound's effect on acute symptom changes and on measures related to long-term joint function in the studied population.


Study Types and Populations

Randomized Controlled Trials (RCTs)

Multiple RCTs have been conducted to evaluate the compound against a placebo or vehicle control. These trials typically tracked changes in key physical markers (e.g., mobility, flexibility) and participant-reported outcomes (e.g., pain scores, quality of life).

Long-Term Observational Studies

Some researchers have published data from longer-term observational studies, following participants for up to two years. These studies primarily sought to understand the long-term changes and general patterns of use observed in real-world settings.

Comparative Research

Some studies have compared outcomes associated with the compound to those of other previously studied interventions, including the recording of safety data. For example, some topical formulations have been compared against vehicle control for reducing the duration of episodes and lesion pain in recurrent herpes labialis.


‍‍ Special Populations Research

Geriatric Use

Studies evaluating the compound in older adult populations (aged 65+) have assessed the reporting of adverse events and whether the measured response varied compared to younger adult participants.

Pediatric Use

Research has been conducted on participants aged 12 and older. Studies in people with a history of liver issues have also been performed to evaluate potential outcomes.

Combination Studies

Studies have examined whether using the compound alongside physiotherapy was associated with a greater change in outcome measures. Some studies have evaluated whether using the compound alongside dietary changes was associated with changes in pain scores; the reported maximum change in scores was 30%.

Key Studies & References

  1. Acyclovir - StatPearls - NCBI Bookshelf
  2. Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review (Used for topical/systemic efficacy comparison)
  3. Public Assessment Report Scientific discussion Aciclovir Accord 200 mg, 400 mg and 800 mg tablets (aciclovir) NL/H (Example of regulatory document for general efficacy/tolerability statements)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Aciclovir Ciclum (FAQ)

Q: What is the difference between Aciclovir Ciclum and other antiviral creams/tablets?

According to official product information, aciclovir is classified as a synthetic nucleoside analog. This means it is chemically designed to specifically interfere with the DNA replication of certain viruses, such as the Herpes simplex and Varicella-zoster viruses. This targeted mechanism of action defines its role compared to other antiviral medications, which may work through different biological processes.

Q: Why is Aciclovir Ciclum sometimes described as a prophylaxis?

Regulatory documents indicate that aciclovir is formally used for the suppression of recurrent Herpes simplex infections. This type of regimen is characterized by administration over a prolonged period, intended to reduce the frequency of outbreaks. Therefore, this preventive strategy aligns with the medical definition of prophylaxis.

Q: Why might a healthcare provider choose Aciclovir Ciclum tablets over a cream?

The choice depends on the infection site and severity. Tablets are used for systemic treatment, which allows the active component to circulate throughout the body for a wider effect, often for suppressing frequent recurrences or treating complex infections. The cream is indicated specifically for the localized treatment of skin lesions, such as cold sores.

Q: Do high-level warnings exist for individuals with pre-existing neurological conditions?

Official safety notes report that neurological adverse events, such as confusion or convulsions, have been observed, although they are generally reversible. Regulatory warnings indicate that certain patient populations, such as older adults or those with existing kidney impairment, have an elevated risk of systemic toxicity, which may increase susceptibility to central nervous system effects.

Q: What general safety information is available for people with liver impairment?

Regulatory safety profiles note that rare adverse effects can include temporary increases in liver-related enzymes and events like hepatitis and jaundice. These effects are generally described as reversible once the treatment is stopped. Unlike for kidney function, no specific dose adjustment rule related to pre-existing liver impairment is noted in the general warnings.

Q: What is the difference between Aciclovir Ciclum and Valtrex (valaciclovir)?

Valaciclovir, which is the active ingredient in Valtrex, is classified as the prodrug of aciclovir. This means that after administration, the body converts valaciclovir into the active component, aciclovir. Both rely on aciclovir as the active substance to exert their therapeutic action against the target viruses.

Q: Is Aciclovir Ciclum suitable for people who have frequent infections?

Official regulatory indications include the suppression of recurrent Herpes simplex infections. This indication involves the use of a prolonged regimen intended for individuals who experience frequent episodes, reflecting the medicine's documented role in this context.

Q: What are the key points patients should know before starting Aciclovir Ciclum?

Official documents highlight several important points, including the need to maintain adequate hydration, especially during high-dose administration, and the importance of monitoring for potential neurological adverse effects in susceptible individuals. Regulatory documents also note the existence of a mandatory requirement for dose modification for individuals with renal impairment.

Q: What precautions are noted regarding driving or operating machinery while taking this medicine?

Official documentation notes that because adverse reactions such as dizziness and somnolence (drowsiness) have been reported, caution regarding driving or operating machinery is required. Official guidance states individuals should be informed of their potential response to the medication before engaging in potentially hazardous activities.

Q: How long does the main active ingredient, aciclovir, stay in the body?

Regulatory pharmacokinetic data describes the median terminal plasma half-life of aciclovir in adults with normal kidney function as approximately 2.5 to 3 hours. The half-life is the measurement used to estimate the time it takes for the medicine to be largely cleared from the body.

Q: Can the cream form of Aciclovir Ciclum be used on any mucous membrane?

Official regulatory information for the topical cream formulation generally specifies its use for skin lesions, such as recurrent cold sores. Precautions often include a note that the cream is not recommended for use on mucous membranes of the mouth or eye.

Q: Does the effectiveness of Aciclovir Ciclum vary by the route of administration?

Regulatory labeling defines distinct uses for each route: Intravenous (IV) administration is reserved for severe systemic infections, Oral administration is for systemic treatment and suppression, and Topical application is for localized lesions. The various routes of administration are established to deliver the level of systemic exposure required for specific therapeutic purposes.

Advertisements

How should Aciclovir Ciclum be stored and disposed of?

How to Store and Dispose of Aciclovir Ciclum

Official Storage Requirements

Aciclovir Ciclum must be stored according to specific regulatory mandates to maintain its quality. The medicine should be stored below 25 C at a controlled room temperature.

Storage Factor Mandatory Condition
Temperature Store below 25 C
Protection Protect from light and moisture
Container Keep in the original container
Safety Keep out of the sight and reach of children

Disposal Instructions

Disposal of unused or expired product must be carried out in accordance with local requirements. Regulatory guidelines state the medicine must not be thrown away via wastewater or household waste unless otherwise instructed. Patients should consult a pharmacist for guidance on medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aciclovir Ciclum found in:

A-Z Index: